Fatshimetrie, the Mpox vaccination campaign in the Democratic Republic of Congo is a resounding success, especially in some provinces where it is being carried out. Dr. Boureima Hama Sambo, World Health Organization representative in the DRC, recently stated that several provinces have achieved a 100% success rate for the first dose of the Mpox vaccine, including Sankuru, Sud-Ubangi and Tshopo.
According to Dr. Boureima Hama Sambo, more than 90% of the targeted population has already received this first dose of vaccine. It is important to note that this vaccine requires two doses to ensure complete immunization. Thus, after a month, the second dose will be administered to ensure optimal protection against Mpox. With these success rates exceeding 90% in six targeted provinces, the vaccination campaign can be described as a success.
This first phase of the campaign mainly targeted three priority groups: health professionals, sex workers and contacts of contacts. This targeted approach illustrates the importance of strategic vaccination to limit the spread of diseases such as Mpox.
However, despite these notable successes, WHO faces major logistical challenges due to the lack of basic infrastructure, including roads, in the affected provinces. This highlights the need to further invest in strengthening logistical capacities to ensure the success of future vaccination campaigns.
To date, approximately 3 million doses of Mpox vaccines are expected in the DRC by the end of the year, which represents a significant step forward in the fight against this disease.
In conclusion, the Mpox vaccination campaign in the DRC demonstrates the success of efforts to protect the population against this disease. It is essential to continue these actions to ensure optimal vaccination coverage and strengthen public health in the country.
This campaign also illustrates the importance of international cooperation and local partnerships to ensure the success of vaccination programmes. By working together, we can overcome logistical challenges and ensure lasting protection against infectious diseases such as Mpox.